LTR Pharma Limited ( (AU:LTP) ) has issued an update.
LTR Pharma Limited has announced a change in its company secretaries, appointing Mr. David Hwang and Ms. Elizabeth Spooner of Confidant Partners as Joint Company Secretaries, effective immediately. This change is part of the company’s compliance with ASX Listing Rules. The company also expressed gratitude to Ms. Shelby Coleman, the outgoing Company Secretary, for her contributions. This appointment is likely to impact the company’s operational communications with the ASX, potentially enhancing its regulatory compliance and strategic positioning.
More about LTR Pharma Limited
LTR Pharma is dedicated to improving men’s health through the commercialization of innovative treatments for erectile dysfunction. The company’s lead product, SPONTAN®, is a fast-acting intranasal spray delivering a PDE5 inhibitor, offering greater control and spontaneity compared to conventional oral therapies. LTR Pharma aims to expand globally by leveraging regulatory milestones, strategic partnerships, and engagement with the medical community.
YTD Price Performance: -36.42%
Average Trading Volume: 696,327
Technical Sentiment Signal: Buy
See more insights into LTP stock on TipRanks’ Stock Analysis page.